Breast cancer, the most common malignancy in women worldwide, is a very heterogeneous disease. The different molecular profiles can be divided into three main subtypes according to hormone receptor (ER and PR) and HER2 (ERBB2) status. Screening is the most important tool in the fight against the disease. More molecular biomarkers are needed to improve diagnostic and therapeutic approaches.
This content is machine-translated. Please contact us if you need professional translation services.
Publikation
- InFo ONKOLOGIE & HÄMATOLOGIE
